IQVIA Holdings Inc. (IQV)
| Previous close | 231.49 |
| Open | 229.31 |
| Bid | 231.03 x 900 |
| Ask | 231.09 x 800 |
| Day's range | 227.40 - 232.46 |
| 52-week range | 128.52 - 237.47 |
| Volume | 301,491 |
| Avg. volume | 941,796 |
| Market cap | 44.247B |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | 109.93 |
| EPS (TTM) | 2.10 |
| Earnings date | 20 Jul 2021 - 26 Jul 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 256.32 |
- Business Wire
U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA’s motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions. The court sanctioned Veeva five separate times in the decision to punish Veeva for its violations of rules in the litigation, including multiple adverse jury instructions, limitations on the use of evidence at trial and an award of legal fees and costs. Specific language from the decision includes:
- Zacks
3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)
IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.
- Business Wire
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.
